Mario Mandalà: New Manuscript on TME Heterogeneity in Melanoma
Mario Mandalà, Director of Medical Oncology at S.M. Misericordia Hospital and an Associate Professor of Medical Oncology at the University of Perugia, shared a post on LinkedIn about a recent article he and his colleagues authored:
“Just out in EJC our manuscript on tumour microenvironment heterogeneity in primary and paired melanoma metastases.
An academic independent study supported by Fondazione AIRC per la Ricerca sul Cancro ETS.
Our study assessed the prognostic impact of TME heterogeneity and investigated the correlation between genetic features and TME cell composition.
We evaluated 221 paired melanoma samples from 91 patients TME immune phenotypes and cell distribution in FFPE whole tumour sections were analyzed using 9 biomarkers (CD3, CD4, CD8, CD20, CD68, CD163, PD-1, PD-L1, FOXP3), classifying samples as desert (D), excluded (E), or inflamed (I). Additionally, genomic pathways were assessed by next-generation sequencing in both primary and paired samples.
Main findings:
- Paired metastases and primary melanomas show a different immune phenotype pattern
- In paired metastases BRAFV600 mutation correlates with an immunosuppressive TME
- In primary melanomas BRAFV600 mutation is not associated with an immunosuppressive TME
- Longitudinal assessment of TME has a prognostic value, correlating with OS outcome in the overall population and patients receiving ICI
Thanks to prof Giuseppe Palmieri, Prof Daniela Massi, Mario Negri Institute in Milan and colleagues from the Italian Melanoma Intergroup.”
Title: Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis
Authors: Mario Mandalà, Filippo Ugolini, Lorenzo Caldirola, Eliana Rulli, Antonella Manca, Maria Cristina Sini, Sara Simi, Gianna Baroni, Silvia Costabile, Vincenzo De Giorgi, Antonio Cossu, Guido Bellezza, Antonio Guadagno, Francesco Spagnolo, Andrea Gianatti, Paola Ghiorzo, Giuseppe Palmieri, Daniela Massi
Read the Full Article in European Journal of Cancer.
More posts featuring Mario Mandalà on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023